Gadareth Higgs shares a company post on two major trends in the biotech industry.
Biotech at a Turning Point: Innovation Meets Existential Challenge.
2025 is shaping up to be a defining year for biotechnology and for companies that are ready to evolve. Two major trends are reshaping the landscape.
Consolidation and strategic M&A. In a bold move, Novartis recently announced a ~$12 billion acquisition of Avidity Biosciences a sign that biopharma giants are doubling down on rare‑disease pipelines and RNA‑based therapies to offset challenges in legacy drugs.
The rise of AI and digital‑first approaches in biotech R&D. At the recent Axios BFD Summit, industry leaders emphasized how AI is accelerating drug discovery, streamlining target screening, and improving efficiency in gene‑driven disease research even as generative AI raises new questions about self‑diagnosis and patient safety.
For biotech leaders, the key is embracing technological innovation, strategic partnerships, and agility in navigating evolving regulations.
What do you think about the evolving role of AI in biotech? Share your insights in the comments below let’s start a conversation!